← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › DRUGS FOR ACID RELATED DISORDERS › DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) › Proton pump inhibitors
dexlansoprazole
A02BC06
Forms & Strengths
- Delayed-release capsules: 30 mg
- Delayed-release capsules: 60 mg
Adult Dosing
- Healing of erosive esophagitis: 60 mg orally once daily for up to 8 weeks
- Maintenance of healed erosive esophagitis: 30 mg orally once daily for up to 6 months
- Symptomatic non-erosive gastroesophageal reflux disease (GERD): 30 mg orally once daily for 4 weeks
Pediatric Dosing
- Pediatric safety and efficacy have not been established in patients younger than 12 years
- Adolescents 12 to 17 years for symptomatic GERD: 30 mg orally once daily for up to 4 weeks
- Adolescents 12 to 17 years for healing erosive esophagitis: 60 mg orally once daily for up to 8 weeks
Indications
- Healing of all grades of erosive esophagitis
- Maintenance of healed erosive esophagitis and relief of heartburn
- Treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD)
Mechanism of Action
- Proton pump inhibitor (PPI) that binds to H+/K+-ATPase in gastric parietal cells
- Suppresses gastric acid secretion via a dual delayed-release formulation prolonging inhibition
- Inhibits both basal and stimulated acid secretion
Contraindications
- Hypersensitivity to dexlansoprazole, lansoprazole, or substituted benzimidazoles
- Concomitant use with rilpivirine-containing products
Adverse Reactions
- Diarrhea
- Abdominal pain
- Nausea
- Upper respiratory tract infection
- Vomiting
- Flatulence
Drug Interactions
- Drugs dependent on gastric pH for absorption (e.g., ketoconazole, iron salts, dasatinib)
- CYP2C19 substrates (e.g., warfarin, methotrexate)
- Rilpivirine (decreased plasma concentrations and loss of therapeutic effect)
- St. John's wort and rifampin (decrease dexlansoprazole concentrations)
Curated Content: Needs Vetting Before Put to Clinical Use